CROI 2014: Interferon-free BMS Combo Cures 90% of Genotype 1 Hepatitis C

An all-oral regimen of daclatasvir, asunaprevir, and BMS-791325 -- without interferon or ribavirin -- led to sustained response in approximately 90% of previously untreated hepatitis C patients, most with hard-to-treat genotype 1a, according to a study presented at the 21st Conference on Retroviruses and Opportunistic Infections this month in ... (more)

http://ift.tt/1jpjv1j